Dr. Robert R. Redfield, MD
Transplant Surgery (Transplant Surgery Physician)
- Medicare participating
At a glance
- Medical school
- University of Maryland School of Medicine (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 64
Licensed in California since 2023, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: University of Maryland School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Transplant Surgery Physician primary
CA license C184403 (first issued 2023; current) -
Surgery Physician
PA license MD436835
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uci Health-Orange Orange, CA
Medical groups
- University Surgeons of Orange A Medical Group (116 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 64
- Services billed
- 609
- Patients’ average age
- 53
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 174 | 31 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 28 | 23 |
| Hospital discharge day management, more than 30 minutes | 18 | 15 |
| Transplantation of donor kidney | 14 | 14 |
| Preparation of donor kidney for transplantation | 13 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 4 companies reported 4 payments worth $1,811 in total to this clinician.
| Regeneron Pharmaceuticals, Inc. | $1,558 |
|---|---|
| Sanofi-aventis U.S. LLC | $122 |
| Dilon Technologies, Inc. | $96.63 |
| Paragonix Technologies, Inc. | $34.54 |
| Consulting Fee | $1,558 |
|---|---|
| Food and Beverage | $253 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. Jan 31, 2025 | Consulting Fee | $1,558 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $77,627 in research payments for these studies, mostly to the institutions running them.
- A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT05092347 - An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT05106387
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.